Monalizumab Biosimilar（Anti-NKG2A / CD94 Reference Antibody） Datasheet DC Chemicals
Description Monalizumab (IPH2201) is an immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A). Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN-γ production, thereby promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma (HNSCC).
Cat.No A374
Name Monalizumab Biosimilar（Anti-NKG2A / CD94 Reference Antibody）

Chemical Properties

CAS 1228763-95-8
Synonyms Monalizumab
pH value Corresponds to reference standard: PASS
Non-reduced CE-SDS >95%
SEC-HPLC >95%
Isoelectric Point Corresponds to reference standard
Bacterial Endotoxins Test
Residual Proteins of Host Cell
Exogenous Residual DNA
Residual protein A
Biological Activity
Osmolality Corresponds to reference standard: PASS
Peptide mapping Corresponds to reference standard: PASS
N-terminal sequence Corresponds to reference standard: PASS

References

Return Policy
If you are in any way unsatisfied with your purchase, you may return any item(s) within 365 days of its original purchase date.
Please provide your Order Number in the email. We strive to reply to all email inquiries within one business day.
Tel: +86-21-58447131
Fax: +86-21-61642470

Email:
sales@dcchemicals.com
order@dcchemicals.com

Website:
www.dcchemicals.com